Placebo-controlled study to test the efficacy of ALAC in patients with chronic cortical myoclonus. 13 patients participated in the study and were randomized to receive ALAC 0.75 g tablets or placebo (ingested two to six ALAC tablets daily) for 3 weeks. Although ALAC was not shown to be effective as an antimyoclonic, tolerability comparable to placebo and a significant improvement in sleep quality and depression were observed.
In fact, after the study, more than half of the subjects decided to continue the supplement with ALAC, also because the quality of sleep and depressive symptoms have a significant impact on the quality of life.
Year: 2011
Nationality: Italy
Download the document